Abstract
Melanoma is the deadliest type of skin cancer. CD20+ melanoma stem cells (CSCs) are pivotal for metastasis and initiation of melanoma. Therefore, selective elimination of CD20+ melanoma CSCs represents an effective treatment to eradicate melanoma. Salinomycin has emerged as an effective drug toward various CSCs. Due to its poor solubility, its therapeutic efficacy against melanoma CSCs has never been evaluated. In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs). Using a single-step nanoprecipitation method, salinomycin-loaded lipid-polymer nanoparticles (SA-NPs) were prepared, then CD20-SA-NPs were obtained through conjugation of thiolated anti-CD20 aptamers to SA-NPs via a maleimide-thiol reaction. CD20-SA-NPs displayed a small size of 96.3 nm, encapsulation efficiency higher than 60% and sustained drug release ability. The uptake of CD20-SA-NPs by CD20+ melanoma CSCs was significantly higher than that of SA-NPs and salinomycin, leading to greatly enhanced cytotoxic effects in vitro, thus the IC50 values of CD20-SA-NPs were reduced to 5.7 and 2.6 μg/mL in A375 CD+20 cells and WM266-4 CD+ cells, respectively. CD20-SA-NPs showed a selective cytotoxicity toward CD20+ melanoma CSCs, as evidenced by the best therapeutic efficacy in suppressing the formation of tumor spheres and the proportion of CD20+ cells in melanoma cell lines. In mice bearing melanoma xenografts, administration of CD20-SA-NPs (salinomycin 5 mg·kg−1·d−1, iv, for 60 d) showed a superior efficacy in inhibition of melanoma growth compared with SA-NPs and salinomycin. In conclusion, CD20 is a superior target for delivering drugs to melanoma CSCs. CD20-SA-NPs display effective delivery of salinomycin to CD20+ melanoma CSCs and represent a promising treatment for melanoma.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Wong DJ, Ribas A . Targeted therapy for melanoma. Cancer Treat Res 2016; 167: 251–62.
Siegel RL, Miller KD, Jemal A . Cancer statistics. CA Cancer J Clin 2016; 66: 290–308.
Gao J, Li W, Guo Y, Feng SS . Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (Lond) 2016; 11: 3261–82.
Xie F, Xu W, Yin C, Zhang G, Zhong Y, Gao J . Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. World J Gastrointest Oncol 2016; 8: 735–44.
Zabierowski SE, Herlyn M . Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 2008; 26: 2890–4.
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328–37.
Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H . Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A 2011; 108: 2474–9.
Pinc A, Somasundaram R, Wagner C, Hormann M, Karanikas G, Jalili A, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther 2012; 20: 1056–62.
Resham K, Patel PN, Thummuri D, Guntuku L, Shah V, Bambal RB, et al. Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells. Chem Biol Interact 2015; 240: 146–52.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645–59.
Naujokat C, Steinhart R . Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012; 2012: 950658.
Yue W, Hamaï A, Tonelli G, Bauvy C, Nicolas V, Tharinger H, et al. Inhibition of the autophagic flux by salinomycin in melanoma stem-like/progenitor cells interferes with their maintenance. Autophagy 2013; 9: 714–29.
Mao X, Liu J, Gong Z, Zhang H, Liu Y, Zou H, et al. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine (Lond) 2015; 10: 2677–95.
Xie F, Zhang S, Liu J, Yang K, Zhang H, Liu Y, et al. Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine (Lond) 2016; 11: 1831–46.
Wang M, Xie F, Wen X, Chen H, Zhang H, Liu J, et al. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. Nanomedicine (Lond) 2017; 12: 1025–42.
Liu Y, Pan J, Feng SS . Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm 2010; 395: 243–50.
Gao J, Chen H, Song H, Su X, Niu F, Li W, et al. Antibody-targeted immunoliposomes for cancer treatment. Mini Rev Med Chem 2013; 13: 2026–35.
Gao J, Xia Y, Chen H, Yu Y, Song J, Li W, et al. Lipid-polymer nanoparticles conjugated anti-EGFR antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond) 2014; 9: 279–93.
Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009; 30: 1627–34.
Gao J, Feng SS, Guo Y . Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) 2010; 5: 1141–5.
Nutiu R, Li Y . Structure-switching signaling aptamers. J Am Chem Soc 2003; 125: 4771–8.
Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R . Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64: 7668–72.
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006; 103: 6315–20.
Wu C, Wan W, Zhu J, Jin H, Zhao TJ, Li HF . Induction of potent apoptosis by an anti-CD20 aptamer via the crosslink of membrane CD20 on non-Hodgkin's lymphoma cells. Rsc Advances 2017; 7: 5158–66.
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16281–6.
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504–14.
Maloney DG . Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366: 2008–16.
Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB . Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806–23.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33.
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32.
Ng EW, Shima DT, Calias P . Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123–32.
Visvader JE, Lindeman GJ . Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717–28.
Acknowledgements
This work was supported by 2017 Shanghai Minhang District Central Hospital Project (2017MHJC01), Fudan University Affiliated Jinshan Hospital Excellent Youth Talent Training Program (2015-2), Shanghai Jinshan District Health Family Planning System Excellent Youth Talent Training Program (JSYQ201605), and the National Natural Science Foundation of China (81302363, 81771964, and 81602358). We thank Sunlipo Biotech Research Center for Nanomedicine (Shanghai, China) for providing technical support in the preparation of nanoparticles.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zeng, Yb., Yu, Zc., He, Yn. et al. Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells. Acta Pharmacol Sin 39, 261–274 (2018). https://doi.org/10.1038/aps.2017.166
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/aps.2017.166
